Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Blue Energy Ord Shs T.BLU


Primary Symbol: BUENF

Blue Energy Limited is an Australia-based oil and gas exploration company. The Company is engaged in the exploration, evaluation and development of conventional and unconventional oil and gas resources. Its geographical segment is Australia, which includes Queensland and the Northern Territory. The Company’s projects include Bowen Basin (ATP814P), Carpentaria Basin (ATP1112A), Galilee Basin (ATP813P), South Georgina Basin (ATP1114A, ATP1117A and ATP1123A), Surat Basin (ATP854P) and Greater McArthur Basin (EP199A, EP200, EP205A, EP206, EP207, EP208A, EP209A, EP210A and EP211A). ATP814P consists of six disconnected blocks in the North Bowen Basin in an area ranging from south of Moranbah up to Newlands in the Northern Bowen Basin. ATP1112A is located in the Carpentaria Basin of northwestern Queensland. It is located south of the Gulf of Carpentaria region and approximately 40 kilometers (km) west of Normanton. ATP813P covers a large area in the Galilee Basin in Central West Queensland.


OTCPK:BUENF - Post by User

Bullboard Posts
Post by dereklion Jun 23, 2016 10:20am
106 Views
Post# 24990783

I will wait for Shigamab

I will wait for ShigamabIn addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for the treatment of sHUS are currently underway. The Company intends to meet with regulatory authorities in 2016 to present its clinical development plan for Shigamab™ in the treatment of sHUS.
Bullboard Posts